Omnix Medical

Executive Summary

Omnix Medical is a Jerusalem-based biopharmaceutical company founded in 2015, focused on developing novel antimicrobial peptide (AMP) antibiotics to combat drug-resistant Gram-negative infections. The company’s platform optimizes and stabilizes AMPs, enhancing their potency and selectivity while overcoming traditional peptide therapeutic limitations. Its lead candidate, OMN51, targets multidrug-resistant Pseudomonas aeruginosa, a critical priority pathogen according to the WHO. With $30 million raised and a preclinical stage, Omnix addresses a major unmet need in infectious disease, where antibiotic resistance poses a growing global threat. The company’s technology has potential applicability to other Gram-negative pathogens, positioning it as a promising player in the next wave of antimicrobial innovation. Omnix’s progress to date includes successful in vitro and in vivo proof-of-concept studies for OMN51, demonstrating bactericidal activity against resistant strains and a favorable safety profile. The company is advancing toward IND-enabling studies, with plans to initiate clinical trials in the near term. Given the urgent demand for new antibiotics, particularly against MDR Pseudomonas, Omnix’s pipeline offers a differentiated approach. The company is actively seeking partnerships to accelerate development and manufacturing scale-up. While still preclinical, the strong scientific foundation and clear regulatory pathway support its potential to become a leading solution in the fight against antimicrobial resistance.

Upcoming Catalysts (preview)

• Q4 2026Initiation of IND-enabling toxicology studies75% success
• Q3 2026Presentation of preclinical efficacy data at a major infectious disease conference60% success
• TBDAnnouncement of a strategic partnership or licensing deal for OMN51 or platform40% success